Historical record - last NADAC publication: 4/17/2024
Product Information
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.1698 per EA under NDC 00054025513. Its NADAC has been published 547 times since Nov 28, 2013.
The Low Outlier badge above means this manufacturer's average price in the Irbesartan and Hydrochlorothiazide market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
12.5; 300 mg/1; mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054025513
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Last Updated
4/17/2024
Active Ingredients
HYDROCHLOROTHIAZIDE; IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA090351On Market Since
10/15/2012
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has been published 547 times since Nov 28, 2013, and over the history we have for it it has declined 66.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1698 per EA |
|---|---|
| All-time high | $0.5110 (Feb 12, 2014) |
| All-time low | $0.1698 (Apr 17, 2024) |
| Median price | $0.3053 |
| Average price | $0.3234 |
| Largest weekly change | +28.6% (Jul 22, 2020) |
| Weeks tracked | 547 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 5 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB, manufactured by Hikma Pharmaceuticals USA Inc., is $0.1698 per EA (NDC 00054025513), effective May 15, 2024.
How has the price of IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB changed over time?
Over the history we have for it, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has declined 66.6%. It has been tracked across 547 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
Since Nov 28, 2013, the NADAC for IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB has ranged from a low of $0.1698 (Apr 17, 2024) to a high of $0.5110 (Feb 12, 2014), with a median of $0.3053 per EA.
Are there cheaper alternatives to IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
5 NADAC-published products share the same active ingredient, strength, and dosage form as IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB, but none are currently priced below it.
Who manufactures IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB?
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB (NDC 00054025513) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification